SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes
Authors:
- 9 December 2023
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 47 (2) , 125-133
Abstract
Introduction Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic agents, with the potential to inhibit breast cancer development. However, the association between SGLT2 inhibitors and risk of breast cancer in human studies is unclear. Objective The aim of our study is to use a large national claims database to assess the association between SGLT2 inhibitor use and risk of breast cancer. Methods We considered a study population of 158,483 adult women with type 2 diabetes who newly initiated SGLT2 inhibitors or dipeptidyl peptidase 4 (DPP4) inhibitors using Optum’s deidentified Clinformatics Data Mart Database between 1 January 2013 and 31 March 2022. The association between SGLT2 inhibitor use and risk of breast cancer was examined using Cox proportional hazard models stratified by age in the overall sample and in a subsample based on propensity score and medication initiation time matching. The effect of medication use duration was explored. Results With an average follow-up of 2.2 years, 2154 breast cancer cases were identified. There was no significant association between SGLT2 inhibitor use and the risk of breast cancer in overall sample (HR = 0.96; 95% CI 0.87, 1.06), in women younger than 51 years old (HR = 0.88; 95% CI 0.59, 1.32), or in women aged 51 years or older (HR = 0.95; 95% CI 0.86, 1.04). The results remained nonsignificant using matching, medication use duration, and sensitivity analyses. Conclusion Our findings suggest SGLT2 inhibitors use was not associated with breast cancer risk compared with DPP4 inhibitors use. Studies with longer follow-up and better adjustments are needed to confirm the finding.Keywords
This publication has 39 references indexed in Scilit:
- Beyond BRCA: New hereditary breast cancer susceptibility genesCancer Treatment Reviews, 2015
- A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and managementJournal of Research in Pharmacy Practice, 2014
- Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- The performance of different propensity score methods for estimating marginal hazard ratiosStatistics in Medicine, 2012
- Body mass index (BMI) and breast cancer: impact on tumor histopatologic features, cancer subtypes and recurrence rate in pre and postmenopausal womenGynecological Endocrinology, 2012
- Diabetes and breast cancer risk: a meta-analysisBritish Journal of Cancer, 2012
- Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitorNature Reviews Drug Discovery, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989
- THE METABOLISM OF TUMORS IN THE BODYJournal of General Physiology, 1927